Apimeds Pharmaceuticals US, Inc. (APUS) vs cbdMD, Inc. (YCBD)
- Apimeds Pharmaceuticals US, Inc. APUS 4.04 −7.97%
- cbdMD, Inc. YCBD 0.35 −2.78%
Apimeds Pharmaceuticals US, Inc. and cbdMD, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $6.6M against $4.0M — 1.6× the size. Apimeds Pharmaceuticals US, Inc. has negative trailing earnings, so its P/E is not meaningful; cbdMD, Inc. trades at 41.2×. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −14.7%) and the higher return on invested capital (−16.0% vs −29.8%). Across the 13 metrics below, cbdMD, Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 6.
Valuation
Profitability
| Metric | APUS | YCBD | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | — | 57.68% | 53.94% |
| Operating margin | 0.00% | (13.87%) | 0.00% |
| Net margin | 0.00% | (14.71%) | 0.00% |
| Free cash flow margin | 0.00% | (11.51%) | 0.00% |
| Return on equity | (100.13%) | (43.01%) | (0.40%) |
| Return on assets | (84.20%) | (26.73%) | (3.32%) |
| Return on invested capital | (15.96%) | (29.78%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack